ArticleBritish journal of cancer2025
Intratumoral bacterial abundance confers poor response to adjuvant gemcitabine in resected pancreatic cancer patients which is mitigated by postoperative antibiotics.
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer.International journal of cancer · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant gemcitabine (aGC) is still a therapeutic mainstay after resection of pancreatic ductal adenocarcinoma (PDAC), but its efficacy is impaired by gram-negative intratumoral bacteria, suggesting a potential therapeutic implication of additive antibiotics. PDAC however, contains several other bacterial strains capable of gemcitabine degradation.
methodsUsing immunohistochemistry and fluorescence-in-situ-hybridization on the samples of a large cohort of resected PDAC patients, we examined how the intratumoral bacterial abundance affected patient outcomes with respect to aGC therapy and whether the use of pre- or postoperative antibiotics (ABT) improved the prognosis. We confirmed the findings in several independent external cohorts.
resultsHigh intratumoral bacterial abundance impaired aGC efficacy (disease free survival (DFS) 9.4 vs 19.1 months, p < 0.001; overall survival (OS) 19.4 vs 34.0 months, p < 0.001), which was mitigated by postoperative ABT application (DFS 7.9 vs 12.4 months, p < 0.001, OS 15.2 vs 29.6 months, p < 0.001). Postoperative ABT improved outcome of patients with low bacterial abundance in their tumors (DFS 15.1 vs 34.8 months, p < 0.001, OS 28.5 vs 56.00 months, p < 0.001).
conclusionsHigh intratumoral bacterial abundance may predict poor response to adjuvant gemcitabine treatment, whereas postoperative ABT improves it. We propose postoperative ABT as potential additive treatment before or during aGC therapy after PDAC resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.